Please provide your email address to receive an email when new articles are posted on . 4D model-guided cardiac resynchronization lead placement improved left ventricular function vs. standard care.
Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...
May 25, 2004 (San Francisco) — Women may encounter more complications during device implantation for cardiac resynchronization therapy (CRT), but ultimately they receive similar benefits from the ...
Cardiac physiologic pacing, also known as cardiac resynchronization therapy, is indicated in patients with heart failure, reduced left ventricular ejection fraction (LVEF) of 50% or less, and either a ...
By Medtronic plc Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart ...
Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results